Drug search by name

Fluphenazine Hydrochloride Injection and NMS

Result of checking the interaction of drug Fluphenazine Hydrochloride Injection and disease NMS for safety when used together.

Check result:

Fluphenazine Hydrochloride Injection <> NMS

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

The central dopaminergic blocking effects of phenothiazines may precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS). NMS is observed most frequently when high-potency neuroleptic agents like haloperidol or fluphenazine are administered intramuscularly but may occur with any agent possessing neuroleptic activity given for any length of time. Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias). Phenothiazine therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients. In patients with a history of NMS, introduction or reintroduction of phenothiazines should be carefully considered, since NMS may recur.

References:

"Product Information. Serentil (mesoridazine)" Boehringer-Ingelheim, Ridgefield, CT.
Grunhaus L, Sancovici S, Rimon R "Neuroleptic malignant syndrome due to depot fluphenazine." J Clin Psychiatry 40 (1979): 99-100
"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation, Buffalo, NY.
"Product Information. Vesprin (triflupromazine)" Bristol-Myers Squibb, Princeton, NJ.
Morris H, McCormick W, Reinarz J "Neuroleptic malignant syndrome." Arch Neurol 37 (1980): 462-3
"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
Price W, Giannini A "A paradoxical response to chlorpromazine: a possible variant of the neuroleptic malignant syndrome." J Clin Pharmacol 23 (1983): 567-9
Dhib-Jalbut S, Hesselbrock R, Brott T, Silbergeld D "Treatment of the neuroleptic malignant syndrome with bromocriptine" JAMA 250 (1983): 484-5
Manser TJ, Warner JF "Neuroleptic malignant syndrome associated with prochlorperazine." South Med J 83 (1990): 73-4
Caroff S, Rosenberg H, Gerber JC "Neuroleptic malignant syndrome and malignant hyperthermia" Lancet 1 (1983): 244
West D "Dangers of fluphenazine." Br J Psychiatry 117 (1970): 718-9
"Product Information. Torecan (thiethylperazine)" Roxane Laboratories Inc, Columbus, OH.
Rampertaap MP "Neuroleptic malignant syndrome." South Med J 79 (1986): 331-6
"Product Information. Temaril (trimeprazine)" Allergan Inc, Irvine, CA.
"Product Information. Trilafon (perphenazine)" Schering Corporation, Kenilworth, NJ.
Zubenko G, Pope HG, Jr "Management of a case of neuroleptic malignant syndrome with bromocriptine." Am J Psychiatry 140 (1983): 1619-20
"Product Information. Stelazine (trifluoperazine)" SmithKline Beecham, Philadelphia, PA.
Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980): 79-83
"Product Information. Compazine (prochlorperazine)." SmithKline Beecham, Philadelphia, PA.
Tenenbein M "The neuroleptic malignant syndrome: occurrence in a 15-year-old boy and recovery with bromocriptine therapy." Pediatr Neurosci 12 (1985): 161-4
"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.
"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb, Princeton, NJ.
Granato JE, Stern BJ, Ringel A, Karim AH, Krumholz A, Coyle J, Adler S "Neuroleptic malignant syndrome: successful treatment with dantrolene and bromocriptine." Ann Neurol 14 (1983): 89-90